Skip to main content
Premium Trial:

Request an Annual Quote

No Deal

Genzyme rejected Sanofi-Aventis' $18.5 billion buyout offer, the New York Times reports. In a letter to Sanofi's Christopher Viehbacher, Genzyme chief executive Henri Termeer says that the $69-a-share offer "provides no new information and no improvement in price, and therefore fails to establish a basis for engagement by the Genzyme board." The Genzyme board, Agence-France Presse notes, had turned down an offer earlier this month, too. "The 'bear hug' letter left open the possibility of discussions between company executives and is typically considered a less aggressive step than going hostile," the Wall Street Journal says, but adds that Sanofi says it is "prepared to consider all alternatives to successfully complete this transaction."

The Scan

Pig Organ Transplants Considered

The Wall Street Journal reports that the US Food and Drug Administration may soon allow clinical trials that involve transplanting pig organs into humans.

'Poo-Bank' Proposal

Harvard Medical School researchers suggest people should bank stool samples when they are young to transplant when they later develop age-related diseases.

Spurred to Develop Again

New Scientist reports that researchers may have uncovered why about 60 percent of in vitro fertilization embryos stop developing.

Science Papers Examine Breast Milk Cell Populations, Cerebral Cortex Cellular Diversity, Micronesia Population History

In Science this week: unique cell populations found within breast milk, 100 transcriptionally distinct cell populations uncovered in the cerebral cortex, and more.